Latest advances in diagnosis and prognosis of ovarian cancer

Ovarian cancer (OvCa), is one of the most lethal of gynaecological malignancies. The current tools, including measurement of CA125 levels remain problematic. It is clear that there would be tremendous benefit to identifying potential biomarkers and evaluating their diagnostic or prognostic clinical utility. Over the past decade, numerous studies have shown the translational value of liquid biopsies (i.e., blood, saliva, CSF, urine) as an alternative to invasive solid tissue biopsies for several cancers. This special issue aims to serve as a forum for discussing the latest biomarkers developments for OvCa using liquid or tissue biopsies. Manuscripts are invited which critically assess the sensitivity and specificity of potential biomarkers, including the opportunity for monitoring real-time disease dynamics through serial monitoring of OvCa patients. Manuscripts that identify patient-specific molecular landscapes and, therefore, better decide on treatment and determine prognostic outcomes, are also invited. Finally, this special issue can also serve as platform where novel technologies can also be discussed. In summary, this special issue aims to provide a balanced overview of advantages and disadvantages of both tissue and liquid biopsies in OvCa.

Submission deadline: 20/06/2024